06/02/2026
My point of view on the Union Budget’s focus on biopharma and healthcare innovation reflected in Deccan Chronicle. Strategic investments in biologics and biosimilars, when aligned with patient needs, have the potential to improve access, affordability, and outcomes at scale. Policy, science, and clinical practice must continue to move forward together to shape the future of healthcare in India.